Tracer library / [177Lu]Lu-vipivotide

[177Lu]Lu-vipivotide

Also written as [Lu-177]Lu-vipivotide
Radionuclide
Lu-177 t½ 9584.6 min
Modality
Therapy
Production route
—
Stage
Approved
Syntheses indexed
0
Bone metastases and bone lesionsProstate cancerPSMA-directed radioligand therapy

What it is

Compound class
PSMA-targeted radioligand (PSMA-617)
Target / mechanism
Prostate-specific membrane antigen (PSMA) PMID 35553387
Clinical application
Metastatic castration-resistant prostate cancer (mCRPC) PMID 35553387
Theranostic pair
—

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

  1. Barriers and solutions in cross-sector care for metastatic prostate cancer patients in Germany: a qualitative study on radioligand therapy.
    2025 · BMC Health Serv Res · Clinical study
  2. Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.
    2022 · Mol Diagn Ther · Clinical study · Phase III

Need this precursor?We can point you to suppliers for [177Lu]Lu-vipivotide, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 39 from PMID 35553387: 'lutetium Lu 177 vipivotide tetraxetan was approved in the USA on 23 March 2022 for the treatment of adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)'.
Ask a question